Study of Nicotine for the Prevention of PONV

The Role of Transcutaneous Nicotine in the Prevention of Postoperative Nausea and Vomiting in Non-smokers

Status

Terminated

Phases

Phase 2

Study type

Interventional

Source

ClinicalTrials.gov

Registry ID

NCT00553709

Acronym

NicoPONV

Enrollment

200

Registered

2007-11-05

Start date

2007-10-31

Completion date

2009-08-31

Last updated

2009-09-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Postoperative Nausea and Vomiting

Keywords

nausea, vomiting, retching, emesis, surgery, anesthesia

Brief summary

The purpose of this study is to determine whether nicotine is effective in the prevention of nausea and vomiting in non-smokers undergoing surgery

Interventions

DRUGNicotine

Nicotinell® Patch 10 cm2, containing 17.5 mg of nicotine, with an average delivery rate of 7 mg of nicotine per 24 hours (= TTS 10)

Study design

Allocation

RANDOMIZED

Intervention model

PARALLEL

Primary purpose

PREVENTION

Masking

QUADRUPLE (Subject, Caregiver, Investigator, Outcomes Assessor)

Eligibility

Sex/Gender

ALL

Age

18 Years to 80 Years

Healthy volunteers

Inclusion criteria

* Adults (18-80 years) * ASA I-II, non-smokers (or ex-smokers who have not been smoking for more than 2 years) * Undergoing elective surgery (ENT, abdominal, urological, gynaecological); and * Consenting to take part in the study will be included.

Exclusion criteria

* Smokers (cigarette, pipe, cigar) * Patients undergoing nicotine replacement therapy * Prolonged postoperative intubation * Postoperative nasogastric tube

Design outcomes

Primary

Measure	Time frame
Prevention of PONV	48 hours postoperatively

Secondary

Measure	Time frame
Adverse effects that may be related to the nicotine patch, for instance, local skin reaction.	48 hours postoperatively

Countries

Switzerland

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026